ICON Early Phase Services is conducting a research study for healthy non-smoking Adults ages 18-55. The purpose of this study is to evaluate the safety and tolerability of multiple doses of an investigational drug to treat HIV. Different oral formulations of the study drug designed to deliver drug over a period of time will be evaluated in this study. In cohort 9, you will be given the FDA approved immediate release drug Edurant (orally with food) daily for 11 days.

Click here to make an appointment for BR 4584-0010 MAD Cohort 9

Or call 210-225-5437 for more information

Vital signs, ECGs, physical examinations, drug and tobacco testing will be performed. Blood and urine samples will also be obtained during this study. 

Participants will complete:

  •  Screening visit
  • 12 Back-to-back overnights

The length of the study from the first admit to end of study is approximately 13 days.

To determine if you fully qualify, it will be necessary to obtain blood samples after an 8- hour fast.  You have the option of fasting for the screening appointment, or, you may return later.   For more information, see below.

Qualified participants may be compensated up to $6,050 for time and travel for completing study participation.


  Cohort 9
Day -7 = COVID test  
Admit Jun 27, 2021 Sun
Discharge July 09, 2021 Fri


If you are able to answer “YES” to the following statements, you may qualify for this study.

  • I am a healthy non-smoking male or female, meaning no significant medical conditions
  • I am between 18 and 55 years old
  • My BMI is between 18.5 and 29.9 kg/m2  and my weight is more than 110 pounds (for men) and more than 99 pounds (for females).
  • I have not participated in a clinical trial and received an investigational drug within 30 days or 5 half-lives( the time it takes for amount of the drug in your body to be reduced by half) of an investigational product prior to dosing
  • If Female, I meet one of the following: 
    • Postmenopausal (no menses for 12 months)
    • Surgically sterile ( hysterectomy, documented tubal ligation, documented tubal occlusion  or documented bilateral oophorectomy)
    • Child bearing and currently use one of the following with a male condom–
      • Hormonal contraceptives (oral, injectable, implant, vaginal ring, patches)
      • IUD (with or without hormonal releasing system)
      • Long term lifestyle of sexual abstinence or only same sex partners
  • If Male, I agree to use one of the following during the study and for 1 week following the last dose of study drug:
    • Male condom and a highly effective hormonal method of contraception (oral, injectable, implant, vaginal ring, patches)
    • Male condom and Intrauterine device
    • Male condom and contraceptive vaginal ring or contraceptive patches
    • Vasectomy with documentation
  • I have suitable veins for multiple blood samples
  • I am able to communicate effectively in English with the study personnel
  • I have not received a vaccination (including influenza) within the 30 days prior to the planned dose

Screening Reminders -

  • 8 hours fasting is required for lab work (only water is allowed)
  • If taking medications, bring them to your screening appointment.
  • Bring a valid, non-expired photo ID with you when you attend your screening visit.  We accept a government issued identification card such as a driver's license, state issued ID card, military ID or passport.  You will be required to show this same photo ID at all study visits.
  •  Arrive 30 minutes before your appointment to complete paper work.
BR 4584-0010 MAD Cohort 9
Healthy Adults
Male or Female
Payment amount
up to $6,050
18 - 55